• Home
  • News
  • Calendar
  • About DF/HCC
  • Membership
  • Visitor Center

Michaela Higgins, MB BCh


  • Fathi AT, Sadrzadeh H, Comander AH, Higgins MJ, Bardia A, Perry A, Burke M, Silver R, Matulis CR, Straley KS, Yen KE, Agresta S, Kim H, Schenkein DP, Borger DR.Isocitrate Dehydrogenase 1 (IDH1) Mutation in Breast Adenocarcinoma Is Associated With Elevated Levels of Serum and Urine 2-Hydroxyglutarate.Oncologist. 2014 Apr 23.
  • Beaver JA, Jelovac D, Balukrishna S, Cochran R, Croessmann S, Zabransky D, Wong HY, Valda Toro P, Cidado J, Blair BG, Chu D, Burns TF, Higgins MJ, Stearns V, Jacobs LK, Habibi M, Lange JR, Hurley PJ, Lauring J, Vandenberg D, Kessler J, Jeter SC, Samuels M, Maar D, Cope L, Cimino-Mathews A, Argani P, Wolff AC, Park BH.Detection of Cancer DNA in Plasma of Early Stage Breast Cancer Patients.Clin Cancer Res. 2014 Feb 18.
  • Reynolds KL, Higgins MJ.Endocrine therapy for breast cancer: a tough pill to swallow.Menopause. 2013 Jul;20(7):714-6.
  • Higgins MJ, Liedke PE, Goss PE.Extended adjuvant endocrine therapy in hormone dependent breast cancer: The paradigm of the NCIC-CTG MA.17/BIG 1-97 trial.Crit Rev Oncol Hematol. 2012 Oct 29.
  • Higgins MJ, Beaver JA, Wong HY, Gustin JP, Lauring JD, Garay JP, Konishi H, Mohseni M, Wang GM, Cidado J, Jelovac D, Cosgrove DP, Tamaki A, Abukhdeir AM, Park BH.PIK3CA mutations and EGFR overexpression predict for lithium sensitivity in human breast epithelial cells.Cancer Biol Ther. 2011 Feb 1;11(3):358-67.
  • Higgins MJ, Baselga J.Breast cancer in 2010: Novel targets and therapies for a personalized approach.Nat Rev Clin Oncol. 2011 Feb;8(2):65-6.
  • Higgins MJ, Stearns V.Pharmacogenetics of endocrine therapy for breast cancer.Annu Rev Med. 2011 Feb 18;62:281-93.
  • Higgins MJ, Wolff AC.The androgen receptor in breast cancer: learning from the past.Breast Cancer Res Treat. 2010 Dec;124(3):619-21.
  • Higgins MJ, Stearns V.CYP2D6 polymorphisms and tamoxifen metabolism: clinical relevance.Curr Oncol Rep. 2010 Jan;12(1):7-15. Review.
  • Higgins MJ, Ettinger DS.Chemotherapy for lung cancer: the state of the art in 2009.Expert Rev Anticancer Ther. 2009 Oct;9(10):1365-78. Review.
  • Higgins MJ, Forastiere A, Marur S.New directions in the systemic treatment of metastatic thyroid cancer.Oncology (Huntingt). 2009 Aug;23(9):768-75. Review.
  • Higgins MJ, Park BH.Expanding role of bisphosphonates in the management of early breast cancer.Expert Rev Anticancer Ther. 2009 Aug;9(8):1051-4.
  • Higgins MJ, Stearns V.Understanding resistance to tamoxifen in hormone receptor-positive breast cancer.Clin Chem. 2009 Aug;55(8):1453-5.
  • Higgins MJ, Wolf AC.Adjuvant endocrine therapy for premenopausal hormone receptor-positive breast cancer; much done, more to do.Oncology (Huntingt). 2009 Jan;23(1):40, 42, 44.
  • Gustin JP, Karakas B, Weiss MB, Abukhdeir AM, Lauring J, Garay JP, Cosgrove D, Tamaki A, Konishi H, Konishi Y, Mohseni M, Wang G, Rosen DM, Denmeade SR, Higgins MJ, Vitolo MI, Bachman KE, Park BH.Knockin of mutant PIK3CA activates multiple oncogenic pathways.Proc Natl Acad Sci U S A. 2009 Feb 24;106(8):2835-40.
  • Higgins MJ, Rae JM, Flockhart DA, Hayes DF, Stearns V.Pharmacogenetics of tamoxifen: who should undergo CYP2D6 genetic testing?.J Natl Compr Canc Netw. 2009 Feb;7(2):203-13. Review.
  • Higgins MJ, Davidson NE.What is the current status of ovarian suppression/ablation in women with premenopausal early-stage breast cancer?.Curr Oncol Rep. 2009 Jan;11(1):45-50. Review.
  • Higgins MJ, Wolff AC.Therapeutic options in the management of metastatic breast cancer.Oncology (Huntingt). 2008 May;22(6):614-23; discussion 623, 627-9. Review.
  • Lee KS, Higgins MJ, Patel BM, Larson JS, Rady MY.Paraneoplastic coma and acquired central alveolar hypoventilation as a manifestation of brainstem encephalitis in a patient with ANNA-1 antibody and small-cell lung cancer.Neurocrit Care. 2006;4(2):137-9.
  • Higgins MJ, Fonseca R.Genetics of multiple myeloma.Best Pract Res Clin Haematol. 2005;18(4):525-36.